MAFSacubitril & Valsartan Tablet, Sacubitril 24 mg + Valsartan 26 mg, Sacubitril 49 mg + Valsartan 51 mg, Sacubitril 97 mg + Valsartan 103 mg
To reduce the risk of cardiovascular death and hospitalisation for heart failure (HF) in patients:
• with chronic HF classified by NYHA Class II-IV symptoms; and
• with left ventricular ejection fraction of 40% or less; and
• who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
• who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.